In addition, patients in the anastrozole group also experienced significantly more hypertension (402 events versus 349, HR, 1.18, P = 0.04) and a trend towards a higher incidence of ischemic cardiovascular events that did not reach statistical significance (most commonly mild-to-moderate angina) in the anastrozole group compared to the tamoxifen group (127 patients, 4.1% versus 104, 3.4%; P = 0.1).
← all excerpts
Clinical utility of aromatase inhibitors as adjuvant treatment in postmenopausal early breast cancer.
1
0.1000
0.1000